welcome
CNBC

CNBC

Health

Health

Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure

CNBC
Summary
Nutrition label

79% Informative

Novo Nordisk's CagriSema failed to show superior outcomes to existing GLP-1 drugs.

The Danish company's next-generation drug Cagrisa is one of its next bets on the obesity market.

Analyst: "Sentiment toward these guys is as negative as it's ever been".

Zealand Pharma CEO Adam Steensberg expects Petrelintide to come to market around 2030 .

Novo Nordisk expects to file for regulatory approval for CagriSema in the first quarter of 2026 .

Still, the company has some way to go to recoup some of the earlier hype around the drug.

VR Score

88

Informative language

93

Neutral language

73

Article tone

formal

Language

English

Language complexity

59

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.